Current methods for assembling biosynthetic pathways in microorganisms require a process of repeated trial and error and have long design-build-test cycles. We describe the use of a cell-free transcription-translation (TX-TL) system as a biomolecular breadboard for the rapid engineering of the 1,4-butanediol (BDO) pathway. We demonstrate the reliability of TX-TL as a platform for engineering biological systems by undertaking a careful characterization of its transcription and translation capabilities and provide a detailed analysis of its metabolic output. Using TX-TL to survey the design space of the BDO pathway enables rapid tuning of pathway enzyme expression levels for improved product yield. Leveraging TX-TL to screen enzyme variants for improved catalytic activity accelerates design iterations that can be directly applied to in vivo strain development.
E. coli has been used to support high-level conversion of valuable chemicals, 16 and a cell-free protein synthesis system has been used to screen enzyme variants. 17 Systematic studies of cellfree systems have monitored the change of pH, measured the change of metabolites over time, and evaluated protein synthesis. [18] [19] [20] Studies have shown that the depletion of ATP is limiting near the beginning of a cell-free reaction, and the consumption of glutamate is critical in regenerating cofactors. [21] [22] [23] A correlation between cell-free and in vivo systems has not been demonstrated. As such, a systematic side-by-side analysis between in vivo and cell-free systems is required for cell-free systems to be considered widely as a prototyping platform for metabolic engineering.
Metabolic pathways consist of multiple parts and factors that are combined in precise combinations to achieve desired functions. Enzyme expression levels and activity affect target product yield. Tuning enzyme expression requires engineering the level of transcription, translation, and enzyme activity. Furthermore, balancing expression of multiple genes in parallel remains a challenge. Often, enzymes are overexpressed when they are identified to be essential for improving target metabolite production. Protein overexpression can affect cell growth 24 and possibly reduce metabolite production. 25 Studies have previously demonstrated the feasibility of tuning protein expression levels in vivo for improving metabolite productions. [26] [27] [28] Cell-free TX-TL system also provides a platform for investigating the correlation between protein expression levels and metabolite production. Cell-free TX-TL system allows simultaneous protein expression from multiple pieces of DNA, including linear DNA. Such properties can be used to verify pathway enzyme expression and activity. Sun et al. ' s work has connected protein expression level in TX-TL to in vivo systems by comparing the expression strength of different promoters. 6 This work takes a further step to compare the dynamics of a metabolic pathway in TX-TL to in vivo systems by correlating protein expression levels to metabolite production in both systems.
This work aims to demonstrate the reduction of traditional metabolic engineering design-buildtest cycles using the 1,4-butanediol (BDO) pathway as a TX-TL prototype. BDO and its derivatives are widely used for producing automotive plastics, electronic chemicals, and elastic fibers. BDO has a projected global market of $8.96 billion by 2019. 29 Historically, BDO has been produced from petrochemical feedstocks, but recently a bio-based process was commercialized. 30 The BDO pathway used for this bioprocess is shown in Figure 1 The main goal of this work is to demonstrate TX-TL as a research tool for metabolic engineering and to establish the feasibility of design space exploration (shown in Figure 1 ). Using the BDO pathway previously developed by Genomatica Inc., 31 we add linear DNA encoding pathway enzymes to TX-TL. We measure the resulting transcriptional and translational outputs and pathway related metabolites. We also use TX-TL to rapidly tune pathway enzyme expression levels for design space exploration of the BDO pathway. Ribosome-binding site (RBS) elements of varying strengths are chosen from the bicistronic design (BCD) library to adequately explore the design space of the BDO pathway in TX-TL. The two Shine-Dalgarno motifs from BCD allows the first one to make a leader peptide to open the second one, which delivers precise and reliable translation initiation. The translational coupling architecture BCD ensures protein expression at expected levels independent of downstream sequence. 32 Through exploring the design space of the BDO pathway in TX-TL and in vivo, we systematically compare the metabolic output and enzyme expression levels. To show the industrial relevance of TX-TL, we demonstrate that the use of linear DNA in TX-TL has the capabilities to serve as a biomolecular breadboard to speed up design iterations, and results from TX-TL can be applied to in vivo strain development.
Figure 1: TX-TL as a platform for engineering biosynthetic pathways. A design-build-test-learn cycle using a BDO pathway previously designed by Genomatica Inc. is shown. Linear DNA that encodes pathway enzymes is added to TX-TL. The transcription and translation machinery and metabolic output of TX-TL are analyzed. The design space of the BDO pathway is explored in TX-TL and in vivo for comparison. Design: Genomatica Inc. previously designed the BDO synthesis pathway. Build: Generate linear DNA with sequences of pathway enzymes under the same promoters, UTRs, and terminators, subsequently tune enzyme expression levels by varying UTR strength, and assemble into plasmids for design space exploration of the BDO pathway. Test: The TX-TL system is analyzed systematically and compared to the in vivo system in parallel. Learn: Systematic analysis of TX-TL through reverse transcription-PCR (RT-PCR), Western blot, and metabolomics. Explore design space: Compare the expression of bottleneck enzyme and BDO production in TX-TL and in vivo.
Results and Discussion
Pathway Verification in TX-TL Pathway enzymes are expressed in TX-TL reactions by adding linear DNA. Linear pieces of DNA are generated by amplifying regions encoding a promoter, a 5'-untranslated region (UTR), a coding sequence of an individual pathway enzyme, and a terminator. End products of TX-TL reactions are directly used for polyacrylamide gel electrophoresis with sodium dodecyl sulfate (SDS-PAGE) preparation, and all enzymes of the BDO pathway show up on the gel at expected sizes (as shown in Figure S1 ). By adding linear DNA encoding enzymes from the BDO pathway sucD (035), 4hbd (036), cat2 (034), ald (025B), and adh (012), we identify that the conversion from 4HB-coA to downstream metabolites is limiting the production of BDO. After 16-hour reactions, more than 10 mM of 4HB is detected, and only 0.5 (± 0.1) mM of BDO is detected. 3 .1 (± 0.1) mM of gamma-butyrolactone (GBL) is also detected. GBL is the lactonized form of 4HB, and it is hypothesized to be produced spontaneously from 4HB-coA via cat2. The production of 4HB and GBL suggests that sucD (035), 4hbd (036), and cat2 (034) are not ratelimiting enzymes for the pathway, and ald (025B) and adh (012) can be rate-limiting. Previous results from Yim et al. 33 and Barton et al. 34 also agree with our observation of such pathway dynamics. We, therefore, hypothesize ald and adh as the bottleneck enzymes for the production of BDO in TX-TL. To better understand TX-TL as a platform for metabolic engineering, we pick a more advanced cat2, ald and adh combination, cat2 (C), ald (C), and adh (C), for studying a wider range of system dynamics. During an initial experiment with the advanced enzymes, 3.4 (± 0.9) mM of BDO is detected, and about 3.2 (± 0.5) mM of GBL is detected.
The conversion from 4HB to BDO requires the TX-TL system to supplement for electron transfer via cofactors. We subsequently test cofactor concentrations for directing metabolic flux into the production of BDO. We focus on cofactors directly related to the last three steps of the BDO pathway: NADP, NADPH, acetyl-coA, and coA. The absence of acetyl-coA or coA added into the TX-TL system results in less BDO, less GBL, but more 4HB. Also, the addition of acetyl-coA instead of coA helps produce more GBL, which translates to more 4HB-coA synthesized. We hypothesize that the TX-TL system needs more acetyl-coA for the BDO pathway. 1 mM of acetyl-coA is added for the rest of the work. The absence of NADP or NADPH does not drastically affect target metabolite production, but the addition of NADPH improves the production of BDO. 4 mM of NADPH is added for rest of the work, and details can be found in Figure S2 . These results suggest that the availability of NADPH in TX-TL is limiting the synthesis of downstream products. Such indicates that more strain engineering around the TCA cycle or the pentose phosphate pathway (PPP) may help resolve cofactor imbalance in TX-TL.
System-level studies in TX-TL
Results from system-level studies of TX-TL system are shown in Figure 2 . For the analysis of transcription and translation, we focus on the bottleneck enzyme ald (C). The characterization of the transcription and translation of ald (C) are carried out by adding linear DNA encoding individual pathway enzymes. We also perform metabolomics on TX-TL reactions to grasp an understanding of the metabolic network.
Transcription
We predict and observe resource limitations of TX-TL by studying the change in mRNA expression dynamics based on how much DNA is added to the TX-TL reaction. Figure 2a shows the mRNA expression of ald (C) from TX-TL reaction added with just linear DNA encoding ald (C) in blue circles. The orange squares show expression of ald (C) from TX-TL reaction added with linear DNA encoding individual pathway enzymes. The blue and orange line are the respective predicted mRNA dynamics generated by the TX-TL modeling toolbox. 35 The linear DNA encoding other pathway enzymes competes with linear DNA encoding ald (C) for transcription. The mRNA expression difference of the peak mRNA value is greater than 80%. Note that 30 nM of linear DNA encoding ald (C) is added, and a total of 60 nM of linear DNA encoding other pathway enzymes is added. The transcription of ald (C) is analyzed using RT-PCR. The background signal from DNA is subtracted. The mRNA level peaks within the first hour and then drops to zero by the end of the first five hours. The rapid degradation of mRNA in TX-TL reflects resource limitations of the system. The dynamics of mRNA in TX-TL is similar to previously reported. 36 
Translation
The expression of ald (C) and adh (C) in TX-TL is analyzed using Western blots and can be normalized by total protein intensities measured from SDS-PAGE. 37 Complete SDS-PAGE and Western blots for the time-course ald (C) expression is shown in Figure S4 . Protein degradation is observed, which is most likely due to the presence of protease in the extract. Extract used in this work is prepared with S138 (MG 1655 △adhE △ldhA △pflB + lpdA*), an engineered E. coli strain previously reported. 33 Most cell-free systems are either developed with purified reagents or with cell lysates from strains with protease deletion. Protein degradation is rarely captured. However, protein degradation is expected here because of the lack of protease gene knockout. The total and soluble protein expression of ald (C) and adh (C) in TX-TL are shown in Figure 2b . Their respective sizes are 60 kDa and 40 kDa. Most of the enzymes remain in the soluble fraction of the TX-TL reactions. The amount of each protein band on the ladder is approximately 200 ng, 38 and the concentration of ald (C) should be on the order of 10 ng/ul.
Metabolomics
To understand the metabolism in TX-TL, we carry out experiments to collect time-course data of metabolites. The production of pathway intermediate 4HB and target metabolite BDO is shown in Figure 2c . The production of 4HB peaks around 4 hours into the reaction. The level of 4HB drops as the compound is converted to downstream metabolites. The concentration of BDO increases as the concentration of 4HB decreases. The concentration of 4HB-coA peaks between 6 and 8 hours, when BDO concentration starts to plateau, and byproducts GBL starts to accumulate (shown in Figure S3d ). We hypothesize that the consumption of glutamate links to cofactor regeneration. The production of BDO depends on two steps of NADPH-dependent electron transfer. The concentration of NADPH drops to the detection limit by the end of the fourth hour into the TX-TL reaction. Since NADPH is a critical cofactor for the synthesis of BDO, the rate of NADPH being reduced should be the same magnitude as the rate of NADPH being oxidized. The ratio of NADPH/NADP is shown in Figure S3b . Carbon flux through the TCA cycle is very weak, but the consumption of glutamate is very prominent. In Figure 2d , the conversion of glutamate reaches 80% by the end of TX-TL reactions. A preliminary 13 C analysis also confirms that glutamate consumption is the primary energy source (data not shown). Furthermore, the conversion from glutamate to α-ketoglutarate reduces NADP to NADPH. The amount of glutamate consumed equals to roughly the sum of 4HB produced, GBL produced, and the BDO produced. The consumption of glutamate is the primary metabolic flux in the TX-TL system.
We learn from the system-level studies that the first few hours are valuable for comparison between pathways or enzyme variants. TX-TL is a resource-limited system: mRNA degradation starts after the first hour, and protein degradation and cofactor imbalance happens. Metabolic flux in TX-TL mainly comes from glutamate, which is also the energy source for regenerating cofactors. Constructing the BDO pathway using parts from the BCD library helps modulate pathway enzyme expression levels in TX-TL and in vivo. Details of construct design can be found in Figure S5 . We generate constructs with varying enzyme expression levels, and the level of soluble ald (C) expression in TX-TL and in vivo are shown in Figure 3a and Figure 3d , respectively. The SDS-PAGE and Western blot images are shown in Figure S6 . BCD 2, BCD 20, and BCD 22 are used to modify protein expression level to high, medium, and low. We have constructed plasmids with ald (C) and adh (C) using a convergent orientation to minimize genetic context effects. 39 The nine different constructs (shown in Table S1 ) show a range of protein expression levels in TX-TL and in vivo. The ald (C) expression levels are similar in TX-TL and in vivo. However, the expression of ald (C) with constructs containing BCD 22 show higher relative expression in vivo versus in TX-TL.
We examine the effect of the expression level of ald (C) on metabolite production in both systems. Although the metabolic output in TX-TL is not exactly the same as the one in vivo, we observe that the production of BDO is closely related to the expression level of the bottleneck enzyme ald (C) in TX-TL and in vivo, which matches with previous studies. 25 The BDO production level from the constructs in the two systems is different. Figure 3b and 3e shows the production levels of BDO from the designed constructs. The BDO production from constructs with strong adh (C) expression are lower in vivo than in TX-TL. As shown in Figure 3b and 3c, BDO production level is linearly correlated to ald (C) expression from constructs containing the same BCD in front of the adh (C) coding region. Overall, the concentration of BDO produced is linearly correlated to the relative expression levels of ald (C) in TX-TL regardless of the expression level of adh (C). As shown in Figure 3e and 3f, the concentration of BDO produced is linearly correlated to the relative expression levels of ald (C) in vivo for some constructs. The expression of adh (C) is overexpressed for constructs containing BCD 2 in front of the coding region of adh (C). Protein overexpression seems to cause a metabolic burden so strong with high adh (C) expression that the production of BDO is limited to about 1 mM regardless of the expression level of ald (C). Data collected from both systems indicates that ald (C) is the bottleneck enzyme of the BDO pathway.
Resource limitation is a more prominent problem in vivo versus TX-TL. The in vivo system carries a larger metabolic burden with more complicating factors such as cell growth and the development of antibiotic resistance. While developing and maintaining the transcription and translation machinery, the in vivo system also fights against the antibiotics in the culture broth. Although we have used promoter pA 40 as part of the constructs, leaky enzyme expression is still a problem. Transformation of constructs containing BCD2 (for strong expression) is problematic. At 37 °C, the production of BDO in vivo is much lower due to metabolic burden (data not shown). At 30 °C, the production of BDO in vivo is comparable to the production of BDO in TX-TL. The production level difference can be the supplement of NADPH and acetyl-coA in the TX-TL system.
The mapping of design space of metabolic pathway from TX-TL to in vivo can be further tuned by repeating the design-build-test cycle shown in Figure 1 . There are two ways to map the two systems more closely. The first way is to redesign plasmid constructs. Re-constructing the pathway with a different set of BCDs, perhaps using BCD 9 or BCD12 instead of BCD 2, can alleviate the metabolic burden in vivo. Using weaker BCDs can potentially avoid overexpression enzymes in vivo, which can more effectively show the linear correlation between ald (C) expression level and BDO production. The second way is to tune protein expression in TX-TL. Plasmid concentration within cells are hard to control, but the expression level of proteins in TX-TL can be tuned by adjusting the concentration of added DNA. 6 In other words, the concentration of the added DNA can be adjusted to map protein expression levels in TX-TL to in vivo. In this work, we have chosen a relatively low DNA concentration to show a linear range of dynamics between ald (C) expression and BDO production. More design iterations will lead to better mapping results.
This work has only used batch mode reaction to compare the two systems strictly. However, both systems can benefit from pH control by feeding base. Cell growth is limited by pH (shown in Figure S9 ), and the pH can be tuned by adjusting buffer. 
High Low
BDO production level ald expression level vivo: blue-strong BCD for adh (C), orange-medium BCD for adh (C), green-weak BCD for adh (C), circle: weak BCD for ald (C), triangle: medium BCD for ald (C), square: strong BCD for ald (C). Error bars show one standard deviation for n ≥ 3 independent experiments.
Application of TX-TL
We apply the TX-TL system to compare three different enzyme combinations of the BDO pathway. The reaction conditions for testing the enzyme combinations are the same. The same sucD (035) and 4hbd (036) are added into TX-TL. The three different enzyme combinations are A: cat2 (034), ald (025B), and adh (012) previously published, 33 B: cat2 (B), ald (B) , and adh (B) previously published, 34 C: evolved version of combination B, cat2 (C), ald (C), adh (C). As shown in Figure 4 , we study the production of BDO, 4HB, and GBL in TX-TL. Combination C results with the greatest BDO production rate, and the production of byproduct GBL is the lowest respectively. The production of 4-HB is very similar for all three combinations, but this could be the conversion to 4-HB is reaching equilibrium by the end of the TX-TL reaction. Since the conversion from glutamate to 4-HB is redox neutral, the accumulated 4-HB is almost the same for all three combinations. Enzyme expression comparison between Combination B and Combination C is shown in Figure 4b . Notably, the expression of ald and adh in combination B is much weaker than the expression of ald and adh in combination C. The engineered enzymes from Combination C is evolved for stability and enzyme specificity for NADPH. 
Conclusion
This work shows that TX-TL can be a reliable engineering platform for metabolic engineering. Through studying transcription, translation, and metabolism in TX-TL, we find that the limitation of the TX-TL system lies within rapid degradation of mRNA and cofactor imbalance.
The main energy source of TX-TL is glutamate, which is different from the in vivo system but this does not impact its ability to produce target metabolites similar to small-scale in vivo synthesis. The ease of adding DNA of interests and tuning protein expression by DNA concentrations opens up unique opportunities for rapidly exploring pathway design space.
Studying the BDO pathway in both TX-TL and in vivo helps confirm that TX-TL is a reliable tool for capturing pathway dynamics. Successfully demonstrating the viability of transcription and translation machinery in S138 extract and the production of BDO provides confidence for future prototyping and engineering in extracts made with advanced E. coli strain or potentially other organisms.
Materials and Methods
Cultivation 48-well plates are used for cell culture and metabolite production. M9 minimal salts medium (6.78 g l −1 Na 2 HPO 4 , 3.0 g l −1 KH 2 PO 4 , 0.5 g l −1 NaCl, 1.0 g l −1 NH 4 Cl, 1 mM MgSO 4 , 0.1 mM CaCl 2 ) is used, and it is supplemented with 10 mM NaHCO 3 , 20 g l −1 D-glucose and 100 mM MOPS to improve the buffering capacity, 10 µg ml −1 thiamine and the appropriate antibiotics. 0.5 mM of IPTG is added to induce enzyme expression. Cell culture starts with overnight growth in LB followed by another overnight growth in minimal media and final culture. The final culture is placed on a shaker at 650 rpm at 30°C or 37°C for cultivation. The culture is centrifuged to collect pellet for protein analysis and supernatant for metabolite analysis.
Cell-Free Expression Preparation and Execution
Fermentations are performed with 1 L initial culture volume in 2-l Biostat B+ bioreactors (Sartorius Stedim Biotech). The temperature is held at 37 °C, and the pH is held at 7.0. Cells are grown aerobically to an optical density (O.D.) of approximately 10, at which point the culture goes through a series of spin-down, re-suspense, and wash cycle according to protocol described by colleagues previously. 41 Collected cell pellets are homogenized using M-110F Microfluidizer Processor and extracted according to the method described by Kwon et al. 42 Analytical Methods LCMS/MS is used to analyze TX-TL samples and supernatant of cell culture. TX-TL samples were first diluted with 1:3 volume ratio with methanol to remove proteins and other big molecules, and then diluted 1: 12.5 with diluent containing labelled internal standards before LCMS analysis. Cell culture samples were diluted 1:50 with same diluent before LCMS analysis. API3200 triple quadrupole system (AB Sciex, Life Technologies, Carlsbad, CA), interfaced with Agilent 1260 HPLC, utilizing electrospray ionization and MRM based acquisition methods is used. BDO and GBL are detected using positive ionization mode, while 4HB and related acidic compounds are detected using negative ionization mode. Zorbax Eclipse XDB C18 4.6x30mm (particle size 1.8um) was used. Column temperature is maintained at 40°C, flow rate of 0.7 mL/min. Injection volume is 5 ul. Eluents include water with 0.1% formic acid (A) and methanol with 0.1% formic acid (B). A fast 1.5 min 5-95% methanol gradient is used, resulting in 1.5 min long LCMS method.
Protein Gel and Western blotting Culture pellets are resuspended with Novagen BugBuster Protein Extraction solution mixed with rLysozyme and benzonase. The amount of BugBuster added is normalized based on the OD value of 1mL culture. Samples are incubated at room temperature for 20 minutes. An equal volume of 2X Laemlii buffer containing 5% of ß-mercaptoethanol is mixed with each sample. The mixture is subsequently boiled in a thermocycler at 99°C for 5 min. 10ul of a mixture containing cell pellets is loaded into each lane, or 5 ul of a mixture containing TX-TL sample is loaded. Invitrogen MagicMarker XP Western Protein Standard and Bio-Rad Kaleidoscope is added as protein ladders. Bio-Rad 4-15% Criterion TGX (Tris-Glycine eXtended) Stain-Free precast gels are used. Gel imaging is done using Bio-Rad Gel Doc EZ Imager for measuring total protein intensity. Invitrogen iblot system is used for gel transfer. Western blot imaging is done using the Chemi Hi Resolution setting on a BioRad ChemiDoc MP imager. The intensity from Western blot is normalized by the total protein from each lane, and stain-free total protein is the loading control for Western Blots. 37 Protein band intensity is determined by using Image Lab 5.2.1.
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